Broadcast

Cardiometabolic Disease in Asia-Pacific Populations

Nikolaus Marx, Azmee Ghazi, David Quek , et al

About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

GDMT & Outcomes in HFrEF: Physician-led Multicentre Experience from Sarawak

Published:

17 March 2026

Citation:

Journal of Asian Pacific Society of Cardiology 2026;5:e11.

Atrial Cardiomyopathy and AF in Heart Failure Substrates

Published:

11 March 2026

Citation:

Arrhythmia & Electrophysiology Review 2026;15:e11.

Corrigendum to: The Short and Sweet on SGLTi and GLP-1 in HF

Published:

06 March 2026

Citation:

US Cardiology Review 2026;20:e04.

Defining AF Cardiomyopathy

Published:

03 March 2026

Citation:

Arrhythmia & Electrophysiology Review 2026;15:e09.